Saturday 17 October 2026
Export PRFX’s income statement to Excel — free account
PainReform Ltd.
PRFX Healthcare Drug Manufacturers Specialty & Generic
PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
0.81
0.04
−4.71%
Follow PRFX
| Jun '26 | Jun '25 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.07 | 1.59 | 0.61 | 1.61 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.67 | |
Capex/Depreciation |
0.00 | 0.00 | (1.25) | (1.75) | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Intangible Assets out of Total Assets |
0.37 | 0.64 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (219.05) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 256.45 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 109.35 | |
Interest Debt per Share |
— | — | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 109.35 | |
Free Cash Flow |
(2.44) | (1.98) | (4.95) | (3.70) | |
Working Capital |
9.54 | 1.45 | (1.90) | 1.99 | |
Capital Expenditures |
0.00 | — | 0.00 | (0.01) | |
Net Current Asset Value |
9.27 | 1.19 | (2.16) | 1.72 | |
| Other line items | |||||
Quick Ratio |
4.93 | 1.42 | 0.57 | 1.33 | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (218.64) | |
Capex per Share |
0.00 | — | 0.00 | (0.41) | |
Average Payables |
0.20 | 0.19 | 0.09 | 0.26 | |
Average Assets |
14.51 | 11.02 | 5.71 | 7.89 | |
Average Common Equity |
11.86 | 8.54 | 2.47 | 5.37 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates